Search results for " Type 2"

showing 10 items of 761 documents

Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registr…

2022

Abstract Aims Type 2 diabetes (T2DM) in patients with coronavirus disease-19 (COVID-19) is associated with a worse prognosis. We separately investigated the associations between the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and dipeptidyl peptidase-4 inhibitors (DPP-4i), and the risk of COVID-19 hospitalization and death. Methods and results Patients with T2DM registered in the Swedish National Patient Registry and alive on 1 February 2020 were included. ‘Incident severe COVID-19’ was defined as the first hospitalization and/or death from COVID-19. A modified Poisson regression approach was applied to a 1:1 propensity sc…

HospitalizationDipeptidyl-Peptidase IV InhibitorsGlucoseDiabetes Mellitus Type 2Glucagon-Like Peptide 1COVID-19 Dipeptidyl peptidase-4 inhibitors (DPP-4i) Glucagon-like peptide-1 receptor agonists Hospitalization Mortality Sodium-glucose cotransporter 2 inhibitorsHumansCOVID-19Pharmacology (medical)RegistriesCardiology and Cardiovascular MedicineGlucagon-Like Peptide-1 Receptor
researchProduct

HEPATITIS C AND DIABETES: THE INEVITABLE COINCIDENCE?

2009

Type 2 diabetes (T2D) and HCV infection are common conditions involving, respectively, at least 170 and 130 million people worldwide. However, the distribution of such cases does not overlap in the same age groups in different geographic areas. Following pioneering reports of increased prevalence of T2D in HCV-positive cirrhosis, interest concerning the relationship between HCV and T2D has escalated. HCV is able to induce insulin resistance (IR) directly and the role of specific viral genotypes responsible for such effect is disputed. IR has consistently been found to be closely linked to fibrosis in HCV infection, although also typically associated with T2D in prefibrotic stages. HCV infec…

Liver CirrhosisMicrobiology (medical)medicine.medical_specialtyCirrhosisHepatitis C virusPopulationHepacivirusType 2 diabetesGlobal Healthmedicine.disease_causeMicrobiologyGastroenterologyRisk FactorsVirologyInternal medicineDiabetes mellitusPrevalencemedicineHumanseducationfatty livereducation.field_of_studydiabetesbusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis C; diabetes; fatty liverHepatitis Cdigestive system diseasesDIABETES HEPATITIS C INSULIN RESISTANCEInfectious DiseasesDiabetes Mellitus Type 2Hepatocellular carcinomaImmunologyInsulin ResistancebusinessViral hepatitis
researchProduct

Role of exercise-induced hepatokines in metabolic disorders.

2019

International audience; The health-promoting effects of physical activity to prevent and treat metabolic disorders are numerous. However, the underlying molecular mechanisms are not yet completely deciphered. In recent years, studies have referred to the liver as an endocrine organ, since it releases specific proteins called hepatokines. Some of these hepatokines are involved in whole body metabolic homeostasis and are theorized to participate in the development of metabolic disease. In this regard, the present review describes the role of Fibroblast Growth Factor 21, Fetuin-A, Angiopoietin-like protein 4, and Follistatin in metabolic disease and their production in response to acute exerci…

medicine.medical_specialtyFGF21PhysiologyEndocrinology Diabetes and MetabolismPhysical activity030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineMetabolic DiseasesRegular exerciseNon-alcoholic Fatty Liver DiseasePhysiology (medical)Internal medicineEndocrine systemMedicineAnimalsHumansObesityMetabolic diseaseBeneficial effectsExercise030304 developmental biology0303 health sciencesbiologybusiness.industry[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism3. Good healthEndocrinologyDiabetes Mellitus Type 2Liverbiology.proteinCytokinesInsulin ResistanceWhole bodybusinessFollistatinAmerican journal of physiology. Endocrinology and metabolism
researchProduct

Metformin and contrast-induced acte kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevati…

2016

IF 4.638; International audience; AIM : To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI).METHODS: Patients with type 2 diabetes mellitus (T2DM) treated with PCI 27μmol/l (0.3mg/dl) or >50% over baseline after PCI. Since PCI was urgent, metformin could not be withheld prior to PCI but was usually stopped after PCI.RESULTS:Among the 372 patients included, 147 (40%) were using metformin, which had older diabetes, but had risk factors similar to patients without metformin. Baseline eGFR was better in pati…

Malemedicine.medical_specialtyendocrine system diseasesMedication Therapy Managementmedicine.medical_treatmentStatistics as TopicContrast Media030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessment03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedbusiness.industryPrimary percutaneous coronary interventionAcute kidney injuryPercutaneous coronary interventionnutritional and metabolic diseasesMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseST segment elevation segment myocardial infarctionMetformin3. Good healthMetforminAcute kidney injuryDiabetes Mellitus Type 2CreatinineConventional PCICardiologyST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular MedicinebusinessKidney diseasemedicine.drug
researchProduct

From obesity to Alzheimer's disease through insulin resistance

2021

Alzheimer's disease is one of the most frequent forms of dementia. It is a progressive neurodegenerative disease, characterized by presence of amyloid plaques and neurofibrillary tangles in the brain. Obesity is regarded as abnormal fat accumulation with deleterious impact on human health. There is full scientific evidence that obesity and the metabolic comorbidities (e.g., insulin resistance, hyperglycaemia, and type 2 diabetes) are related to Alzheimer's disease and likely in the causative pathway. Numerous studies have identified several overlapping neurodegenerative mechanisms, including oxidative stress, mitochondrial dysfunction, and inflammation. In this review, we present how obesit…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismType 2 diabetesmedicine.disease_causeEndocrinologyInsulin resistanceDownregulation and upregulationAlzheimer DiseaseInternal medicineDiabetes mellitusInternal MedicinemedicineHumansDementiaObesityNeurodegenerationInflammationbusiness.industryNeurodegenerationBrainInsulin resistanceAlzheimer's diseasemedicine.diseaseEndocrinologyDiabetes Mellitus Type 2LipotoxicitybusinessOxidative stressJournal of Diabetes and its Complications
researchProduct

Frailty Is Associated with Oxidative Stress in Older Patients with Type 2 Diabetes

2021

Aging has increased the prevalence of frailty, and type 2 diabetes (T2D) has also increased in prevalence. Diabetes and oxidative stress (OS) have been shown to be related to frailty. However, the exact mechanism by which it occurs is not fully known. Our aim was to analyze body composition in community-dwelling older diabetic people treated in our center and to evaluate the possible relation between OS, frailty, and body composition. We included 100 adults older than 65 years with T2D. We found that 15% were frail and 57% were prefrail. The patients included in the nonrobust group showed increased levels of OS. Our study shows that the presence of T2D in the geriatric population is associa…

Malemedicine.medical_specialtyPopulationType 2 diabetesfrailtymedicine.disease_causeArticleCohort StudiesProtein CarbonylationOlder patientsGeriatric populationInternal medicineDiabetes mellitusMalondialdehydemedicinePrevalenceHumansoxidative stressTX341-641educationAgededucation.field_of_studybody compositionNutrition and Dieteticsdiabetesbusiness.industryNutrition. Foods and food supplyagingmedicine.diseaseDiabetes Mellitus Type 2Linear ModelsFemalebusinessOxidative stressFood ScienceNutrients
researchProduct

Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving…

2017

Aims The aim of the study was to investigate the effect of sequential treatment escalation with empagliflozin and linagliptin on laboratory markers of alpha- and beta cell function in patients with type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin monotherapy. Methods Forty-four patients with T2DM received 25 mg empagliflozin for a duration of one month in an open-label fashion (treatment period (TP 1). Thereafter, patients were randomised to a double-blind add-on therapy with linagliptin 5 mg or placebo (TP 2) for one additional month. Alpha- and beta cell function were assessed with a standardised liquid meal test (LMT) and an intravenous (iv.) glucose challenge. Effi…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismLinagliptinType 2 diabetes030204 cardiovascular system & hematologyLinagliptinGlucagon03 medical and health sciences0302 clinical medicineEndocrinologyDouble-Blind MethodGlucosidesInternal medicineInsulin-Secreting CellsInternal MedicinemedicineEmpagliflozinHumansHypoglycemic AgentsInsulinBenzhydryl CompoundsProinsulinAgedbusiness.industryInsulinMiddle Agedmedicine.diseaseGlucagonPostprandial PeriodMetforminEndocrinologyPostprandialTreatment OutcomeDiabetes Mellitus Type 2Glucagon-Secreting CellsGlucose Clamp TechniqueFemalebusinessmedicine.drugProinsulinDiabetes, obesitymetabolism
researchProduct

Disturbed Lipid Metabolism in Diabetic Patients with Manifest Coronary Artery Disease Is Associated with Enhanced Inflammation

2021

Background: Diabetic vasculopathy plays an important role in the pathophysiology of coronary artery disease (CAD) with oxidative stress as a strong mediator. This study aims to elucidate the underlying pathomechanisms of diabetic cardiac vasculopathy leading to coronary disease with an emphasis on the role of oxidative stress. Therefore, novel insights into antioxidant pathways might contribute to new strategies in the treatment and prevention of diabetic CAD. Methods: In 20 patients with insulin-dependent or non-insulin dependent diabetes mellitus (IDDM/NIDDM) and 39 non-diabetic (CTR) patients, myocardial markers of oxidative stress, vasoactive proteins, endothelial nitric oxide synthase …

medicine.medical_specialtyHealth Toxicology and MutagenesisInflammationmedicine.disease_causeArticleCoronary artery diseaseEnosDiabetes mellitusInternal medicinemedicineHumansoxidative stressbiologybusiness.industrydyslipidemiaPublic Health Environmental and Occupational HealthRLipid metabolismLipid Metabolismmedicine.diseasebiology.organism_classificationHeme oxygenaseEndocrinologynutritionDiabetes Mellitus Type 2inflammationdiabetes mellitusMedicinemedicine.symptombusinesschronic diseaseDiabetic AngiopathiesOxidative stressDyslipidemiacoronary artery diseaseInternational Journal of Environmental Research and Public Health
researchProduct

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

2018

Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might …

Blood GlucoseEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetesDiseaseReview Article030204 cardiovascular system & hematologyBioinformaticslcsh:Diseases of the endocrine glands. Clinical endocrinologyIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusmedicineHumansHypoglycemic AgentsCause of deathSistema cardiovascularlcsh:RC648-665DiabetisLiraglutidebusiness.industrySemaglutidemedicine.diseaseClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesHeart failureMalaltiesbusinessmedicine.drugJournal of Diabetes Research
researchProduct

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations fr…

2022

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have …

Diabetes Mellitus Type 2Cardiovascular DiseasesGlucagon-Like Peptide 1HumansHypoglycemic AgentsAlgorithm Cardiovascular outcomes trials GLP-1 receptor agonists Treatment Type 2 diabetes mellitusLiraglutideCardiology and Cardiovascular MedicineAlgorithm ; Cardiovascular outcomes trials ; GLP-1 receptor agonists ; Treatment ; Type 2 diabetes mellitus.Glucagon-Like Peptide-1 ReceptorInternational Journal of Cardiology
researchProduct